|
Gene: DUSP14 |
Gene summary for DUSP14 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DUSP14 | Gene ID | 11072 |
Gene name | dual specificity phosphatase 14 | |
Gene Alias | MKP-L | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | O95147 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11072 | DUSP14 | LZE4T | Human | Esophagus | ESCC | 1.17e-13 | 5.05e-01 | 0.0811 |
11072 | DUSP14 | LZE7T | Human | Esophagus | ESCC | 6.42e-05 | 5.90e-01 | 0.0667 |
11072 | DUSP14 | LZE24T | Human | Esophagus | ESCC | 2.38e-24 | 1.00e+00 | 0.0596 |
11072 | DUSP14 | P1T-E | Human | Esophagus | ESCC | 5.40e-05 | -1.68e-02 | 0.0875 |
11072 | DUSP14 | P2T-E | Human | Esophagus | ESCC | 8.02e-09 | 1.80e-01 | 0.1177 |
11072 | DUSP14 | P4T-E | Human | Esophagus | ESCC | 4.06e-25 | 7.72e-01 | 0.1323 |
11072 | DUSP14 | P5T-E | Human | Esophagus | ESCC | 1.94e-28 | 7.44e-01 | 0.1327 |
11072 | DUSP14 | P8T-E | Human | Esophagus | ESCC | 3.83e-04 | 1.82e-01 | 0.0889 |
11072 | DUSP14 | P9T-E | Human | Esophagus | ESCC | 1.33e-22 | 8.27e-01 | 0.1131 |
11072 | DUSP14 | P10T-E | Human | Esophagus | ESCC | 4.03e-21 | 2.28e-01 | 0.116 |
11072 | DUSP14 | P11T-E | Human | Esophagus | ESCC | 5.53e-14 | 1.08e+00 | 0.1426 |
11072 | DUSP14 | P12T-E | Human | Esophagus | ESCC | 9.77e-46 | 1.19e+00 | 0.1122 |
11072 | DUSP14 | P15T-E | Human | Esophagus | ESCC | 2.33e-40 | 1.22e+00 | 0.1149 |
11072 | DUSP14 | P16T-E | Human | Esophagus | ESCC | 5.75e-08 | 1.75e-01 | 0.1153 |
11072 | DUSP14 | P17T-E | Human | Esophagus | ESCC | 4.59e-05 | 4.79e-01 | 0.1278 |
11072 | DUSP14 | P20T-E | Human | Esophagus | ESCC | 2.19e-05 | 2.96e-01 | 0.1124 |
11072 | DUSP14 | P21T-E | Human | Esophagus | ESCC | 7.96e-40 | 1.16e+00 | 0.1617 |
11072 | DUSP14 | P22T-E | Human | Esophagus | ESCC | 8.40e-16 | 4.93e-01 | 0.1236 |
11072 | DUSP14 | P23T-E | Human | Esophagus | ESCC | 3.83e-11 | 4.75e-01 | 0.108 |
11072 | DUSP14 | P24T-E | Human | Esophagus | ESCC | 2.50e-09 | 4.19e-01 | 0.1287 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:000647016 | Oral cavity | LP | protein dephosphorylation | 89/4623 | 281/18723 | 4.60e-03 | 2.93e-02 | 89 |
GO:000647010 | Prostate | BPH | protein dephosphorylation | 78/3107 | 281/18723 | 1.53e-06 | 2.63e-05 | 78 |
GO:00163118 | Prostate | BPH | dephosphorylation | 98/3107 | 417/18723 | 1.53e-04 | 1.35e-03 | 98 |
GO:000647014 | Prostate | Tumor | protein dephosphorylation | 76/3246 | 281/18723 | 2.86e-05 | 3.46e-04 | 76 |
GO:001631113 | Prostate | Tumor | dephosphorylation | 98/3246 | 417/18723 | 7.31e-04 | 5.08e-03 | 98 |
GO:000647024 | Skin | cSCC | protein dephosphorylation | 111/4864 | 281/18723 | 4.10e-07 | 7.96e-06 | 111 |
GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
GO:000647020 | Thyroid | PTC | protein dephosphorylation | 123/5968 | 281/18723 | 1.69e-05 | 1.77e-04 | 123 |
GO:0006470111 | Thyroid | ATC | protein dephosphorylation | 129/6293 | 281/18723 | 1.11e-05 | 1.09e-04 | 129 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUSP14 | SNV | Missense_Mutation | novel | c.350N>A | p.Arg117His | p.R117H | O95147 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.395T>G | p.Val132Gly | p.V132G | O95147 | protein_coding | deleterious(0) | benign(0.404) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.244N>A | p.Pro82Thr | p.P82T | O95147 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.491A>C | p.Gln164Pro | p.Q164P | O95147 | protein_coding | deleterious(0.01) | benign(0.049) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
DUSP14 | SNV | Missense_Mutation | novel | c.284A>G | p.Asp95Gly | p.D95G | O95147 | protein_coding | deleterious(0.02) | benign(0.087) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
DUSP14 | SNV | Missense_Mutation | rs368619264 | c.50N>A | p.Arg17Gln | p.R17Q | O95147 | protein_coding | tolerated(0.62) | possibly_damaging(0.602) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | rs562478056 | c.398N>A | p.Cys133Tyr | p.C133Y | O95147 | protein_coding | deleterious(0) | benign(0.274) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.20N>A | p.Ser7Asn | p.S7N | O95147 | protein_coding | tolerated(0.47) | benign(0) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
DUSP14 | SNV | Missense_Mutation | rs751469260 | c.454G>A | p.Val152Ile | p.V152I | O95147 | protein_coding | tolerated(0.43) | benign(0) | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.569N>C | p.Arg190Pro | p.R190P | O95147 | protein_coding | deleterious(0.01) | possibly_damaging(0.51) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |